Rosacea Treatment Using Non-thermal (cold) Atmospheric Plasma Device
NCT ID: NCT05592548
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2024-01-02
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study
Single arm study: split face treatment
cold atmospheric plasma
Cold atmospheric plasma will be generated on the skin surface using an electric device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cold atmospheric plasma
Cold atmospheric plasma will be generated on the skin surface using an electric device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to complete six weeks of twice-weekly treatments
Exclusion Criteria
* previous failure of topical ivermectin treatment
* presence of any other facial dermatoses
* presence of any photosensitizing disorders
* systemic tetracycline, systemic or topical ivermectin treatment within 6 weeks of start date
* current or within prior 3 months treatment with systemic immune-suppressive medication
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Skin Center Dermatology Group
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Friedman, MD PhD
Role: PRINCIPAL_INVESTIGATOR
The Skin Center Dermatology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Skin Center Dermatology Group
New City, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Malik S, Gill M, Fridman G, Fridman A, Friedman PC. Cold atmospheric plasma reduces demodex count on the face comparably to topical ivermectin, as measured by reflectance confocal microscopy. Exp Dermatol. 2022 Sep;31(9):1352-1354. doi: 10.1111/exd.14584. Epub 2022 May 11. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ROSACECAPRCM
Identifier Type: -
Identifier Source: org_study_id